• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Delayed treatment of glaucoma increases cost of care


Attempts to delay glaucoma progression will lower the cost of care, according to a study published last month in the Archives of Ophthalmology. Investigators reviewed 151 records of patients with primary open-angle or normal-tension glaucoma, suspected glaucoma, or ocular hypertension.

As disease severity worsened, investigators found increases in direct ophthalmology-related resource use (i.e., ophthalmology visits, glaucoma surgeries, and medication use).

Investigators also found the average direct cost of treatment ranged from $625 per year for patients with suspected glaucoma or early-stage glaucoma compared with $2,511 per year for end-stage glaucoma.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.